However, the above statistics show that it is not less frequent in other epithelial cancer types, and MET amplification is one of the frequent aquired alterations (5–20% of patients) upon resistance towards EGFR tyrosine kinase inhibitor (TKI) therapies in lung cancer [39]. The gene discussed is MET; the disease is lung carcinoma.